ArticlePloS one2025
A qualitative study to investigate pharmacovigilance systems in Dubai hospitals.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Barriers to Adverse Drug Reaction Reporting Among Physicians, Nurses, and Pharmacists: A Scoping Review Comparing High-Income Versus Low-/Middle-Income Countries.Healthcare (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnsuring the safety of medications is a significant public health priority, with developed countries implementing robust pharmacovigilance programs. Despite this, healthcare providers continue to underreport adverse drug reactions (ADRs). This study aims to explore the existing pharmacovigilance system and procedure followed for ADR reporting in selected Dubai hospitals. It also identifies the obstacles that may negatively influence ADR reporting.
methodsThis study was conducted using a qualitative methodology involving in-depth interviews. Convenience sampling was used to select and interview chief hospital pharmacists in Dubai using a semi-structured interview guide. Every interview was audio recorded, verbatim transcribed, and then subjected to a thematic content analysis. The data were analyzed manually by the reading and re-reading of the interviews, and an inductive and flexible approach was undertaken by the research team.
resultsA total of ten individuals, three chief pharmacists and seven pharmacy managers were interviewed. Seven themes emerged from the interviews' thematic content analysis, including: (1) Existence of a pharmacovigilance center or unit, (2) Experience with medication safety & ADR concept, (3) Current ADR reporting process in the hospital setting, (4) Barriers to adverse drug reaction reporting, (5) Policy change needs, (6) The factors that could enhance ADR reporting, and (7) Future pharmacovigilance research needs in the UAE. Eight hospitals have ADR reporting systems in their hospital policies while two hospitals don't have any pharmacovigilance system. Of the eight hospitals, seven have their own software for ADR reporting and one used paper form. Based on the participants feedback, six have full experience with ADR reporting process, while others have partial or don't have any idea about reporting process. ADR reporting is hindered by a number of factors, such as inadequate awareness and training for pharmacovigilance and ADR reporting process, a communication gap between hospitals and regulatory bodies, time constraints due to numerous responsibilities, and fear of punishment.
conclusionThe study found that although hospital pharmacists have a good understanding of medication safety and ADR reporting, they do not actually apply this knowledge into practice. Ongoing training and education on the ADR reporting process have the potential to improve attitudes toward ADR reporting and actively engage individuals in ensuring medication safety within hospital settings. The participation of key stakeholders from the Ministry of Health, academia, the pharmaceutical companies, and healthcare professionals is essential to support the safe and effective use of medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.